Healthcare Services

Global Familial Adenomatous Polyposis Treatment Market Expected to Reach $2.53 Billion by 2030 with 11.1% CAGR

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Familial Adenomatous Polyposis Treatment Market Across 2026–2030?

The familial adenomatous polyposis treatment market size has seen swift expansion in recent years. This market is set to grow from $1.5 billion in 2025 to $1.66 billion in 2026, registering a compound annual growth rate (CAGR) of 11.3%. The historical period’s growth can be linked to the prompt identification of inherited colorectal disorders, an increase in genetic testing availability, the wider reach of colorectal cancer prevention programs, greater awareness of hereditary cancers, and enhancements in endoscopic technologies.

The familial adenomatous polyposis treatment market is projected to experience swift expansion in the coming years. This market is anticipated to reach $2.54 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.1%. Factors contributing to this growth during the forecast period include progress in gene-based therapies, a greater embrace of personalized treatment strategies, the broadening of preventive oncology initiatives, increased utilization of AI-assisted diagnostic tools, and a surge in investment for rare disease research. Key trends identified for the forecast timeframe encompass an intensified emphasis on genetic screening and counseling, a heightened application of preventive surgical procedures, a growing acceptance of targeted drug treatments, the broadening of long-term surveillance efforts, and the incorporation of AI into the early detection of cancer risk.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23396&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Familial Adenomatous Polyposis Treatment Market?

The escalating healthcare expenditures are projected to stimulate growth in the familial adenomatous polyposis (FAP) treatment market. Healthcare spending encompasses the total outlay by individuals, governments, and private entities on medical services, treatments, pharmaceuticals, and health-related infrastructure aimed at maintaining and improving health outcomes. This increase in healthcare spending is attributed to an aging global population and significant advancements in medical technology. As life expectancy rises, a greater number of elderly individuals require long-term care, management of chronic diseases, and frequent medical interventions, all of which contribute to higher healthcare costs. Consequently, this expanded healthcare spending fuels research and development for familial adenomatous polyposis (FAP) treatment, leading to innovations in genetic testing, targeted therapies, and minimally invasive procedures that enhance early detection, disease management, and patient outcomes. For instance, according to the Centers for Medicare & Medicaid Services, a US-based federal agency, Medicare spending in the US surged by 8.1% to reach $1,029.8 billion in December 2024, representing 21% of total national health expenditures (NHE). Therefore, the increasing healthcare spending is a primary driver for the expansion of the familial adenomatous polyposis (FAP) treatment market. The growing adoption of minimally invasive procedures is expected to propel the familial adenomatous polyposis (FAP) treatment market forward. Minimally invasive procedures are medical techniques that employ small incisions, specialized instruments, or imaging guidance to diagnose or treat conditions, resulting in less trauma, quicker recovery times, and lower risks compared to traditional surgery. The rise in these procedures is due to continuous advancements in medical technology and increasing patient demand for faster recuperation. Innovations in surgical techniques, robotics, and imaging have facilitated procedures with smaller incisions, thereby reducing complications and shortening hospital stays. For familial adenomatous polyposis (FAP) treatment, minimally invasive procedures improve polyp removal and surveillance by enabling early detection, precise excision, and fewer complications, which helps to delay disease progression and minimize the need for extensive surgeries. For example, in 2023, the American Society of Plastic Surgeons, a US-based medication company, recorded a 7% year-over-year increase in minimally invasive procedures across the USA. Thus, the proliferation of minimally invasive procedures is a key factor driving the growth of the familial adenomatous polyposis treatment market.

What Segmentation Levels Are Considered In The Familial Adenomatous Polyposis Treatment Market?

The familial adenomatous polyposis treatment market covered in this report is segmented –

1) By Product Type: Icosapent, Eflornithine Hydrochloride, Aspirin, Cetuximab Oral Formulation (CEQ)-508, Other Product Types

2) By Disease Type: Attenuated FAP, Familial Adenomatous Polyposis, Gardner Syndrome, Turcot Syndrome

3) By Symptoms: Bloody Stool, Unexplained Diarrhea, Abdominal Cramps, Bloating , Weight Loss, Lethargy And Vomiting

4) By Application: Colorectal Cancer Prevention, Genetic Counseling, Surgical Treatment

5) By End-Users: Clinics, Hospitals, Diagnostic Centres, Home Healthcare, Other End-Users

Subsegments:

1) By Icosapent: High-Purity Icosapent, Combination Formulations, Extended-Release Icosapent

2) By Eflornithine Hydrochloride: Oral Eflornithine Hydrochloride, Topical Eflornithine Hydrochloride, Intravenous Eflornithine Hydrochloride

3) By Aspirin: Low-Dose Aspirin Therapy, Enteric-Coated Aspirin, Buffered Aspirin

4) By CEQ-508: Monotherapy CEQ-508, Adjunctive CEQ-508 Therapy, Targeted CEQ-508 Formulations

5) By Other Product Types: Genetic Testing Kits And Biomarkers, Endoscopic Surveillance Devices, Surgical Instruments And Medical Implants, Probiotics And Microbiome Modulators, Bowel Preparation Solutions, Dietary Supplements And Nutraceuticals

What Trends Are Projected To Affect The Familial Adenomatous Polyposis Treatment Market?

Leading firms in the familial adenomatous polyposis (FAP) treatment market are achieving notable progress in therapies aimed at improving patient results and delivering novel options. Such breakthroughs encompass novel drug formulations and specific therapies designed to lessen polyp development and curb the disease’s advancement. An example of this is the encouraging outcomes revealed in June 2024 by Biodexa Pharmaceuticals PLC, a UK biopharmaceutical company, from its Phase 2 clinical trial of eRapa for FAP treatment. This trial indicated a 75% non-progression rate and a median decrease of 17% in polyp burden over a 12-month period. Furthermore, participants in Cohort 2 exhibited an even greater 81% non-progression rate and a 29% reduction in polyps when using a particular dosing regimen. The therapy proved to be well-received, evidenced by a 95% compliance rate. These encouraging findings pave the way for a Phase 3 trial involving around 168 high-risk FAP patients, potentially transforming the treatment strategy from surgical intervention to impactful medical therapy.

Which Leading Firms Are Contributing To The Growth Of The Familial Adenomatous Polyposis Treatment Market?

Major companies operating in the familial adenomatous polyposis treatment market are Mayo Clinic, Mount Sinai Health System, Johns Hopkins Medicine, Cleveland Clinic, UCLA Health, Houston Methodist Hospital, Scripps Health, Duke University Health System, Texas Children’s Hospital, Massachusetts General Hospital, Inova Health Care Services, Brigham and Women’s Hospital, Stanford Health Care, Barnes-Jewish Hospital, Northwestern Medicine, Geisinger Health, Max Healthcare, Sapience Therapeutics Inc., Frederick Gastroenterology Associates PA, Therapyx

Read the full familial adenomatous polyposis treatment market report here:

https://www.thebusinessresearchcompany.com/report/familial-adenomatous-polyposis-treatment-global-market-report

Which Regions Are Projected To Dominate The Familial Adenomatous Polyposis Treatment Market In The Coming Years?

North America was the largest region in the familial adenomatous polyposis (FAP) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the familial adenomatous polyposis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Familial Adenomatous Polyposis Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23396&type=smp

Browse Through More Reports Similar to the Global Familial Adenomatous Polyposis Treatment Market 2026, By The Business Research Company

Genes Therapy Global Market Report

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Hereditary Breast And Ovarian Cancer Syndrome Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/hereditary-breast-and-ovarian-cancer-syndrome-treatment-global-market-report

Nucleic Acid Based Gene Therapy Global Market Report

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795